As we begin to reopen Rush University Medical Center for elective procedures and in-person care, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.


French German Italian Portuguese Russian

Parkinson’s Disease and Movement Disorders Program — Clinical Trials

Huntington's Disease Cohort Prospective Registry Study

ENROLL-HD: A prospective registry study in a global Huntington’s disease cohort

INSIGHTS Study: Investigational Drug Treatment for Patients with Advanced Parkinson's Disease

INSIGHTS study: An open-label, randomized 26-week study comparing levodopa-carbidopa INteStInal gel (LCIG) THerapy to optimized medical treatment (OMT) on non-motor symptoms (NMS) in subjects with advanced Parkinson's disease.

Medication Treatment Study for snOH in Subjects with Primary Autonomic Failure

Phase 3 clinical effect of TD-9855 for treating snOH in subjects with primary autonomic failure.

Parkinson's Disease and Levodopa-Induced Dyskinesia Treatment Study

Study of how well a study drug called dipraglurant (ADX48621) works compared to placebo in patients with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID).

Study of Diet-Microbiome Interactions and Parkinson’s Disease

Diet-microbiome interactions and Parkinson’s disease.

Study of Genes Associated with Parkinson’s Disease

Study of genes associated with Parkinson’s disease (PD) from people all over the world.

Study to Determine the Changes in Cognition in Patients with Parkinson’s Disease

Study to identify genetic forms of Parkinson’s disease and determine how cognition changes in these subjects.

Tempo-1 Trial: Parkinson’s Disease Treatment Study

A phase 3, double-blind, randomized, placebo-controlled, parallel-group, 27-week trial to evaluate the efficacy, safety, and tolerability of two fixed doses of tavapadon in early Parkinson’s disease (Tempo-1 trial).

Treatment Study for Adults with Early Manifest Huntington Disease

Study of a recombinant DNA gene therapy treatment for safety and proof-of-concept (POC) of AMT-130 in adults with early manifest Huntington disease (HD).

Treatment Study for Idiopathic Parkinson’s Disease

A phase 2 study to evaluate the safety, tolerability and initial efficacy of pramipexole ER, given with aprepitant in patients with idiopathic Parkinson’s disease.